# hepatocellular carcinoma (HCC) - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 48161
- Completion tokens: 30119
- Reasoning tokens: 13450
- Total tokens: 78280
- API requests reported: 3
- Elapsed seconds: 57.593
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: Google Gemini

---
### Data Quality & Statistical Integrity Warning

The supplied prognostic ledger exhibits extreme statistical properties that require immediate caution:
* **Numerical Saturation and Perfect Separation:** 97 of the 100 features have extreme risk-associated hazard ratios (predominantly identical saturated values of $\text{HR} = 5.185 \times 10^{21}$ or extreme values like $\text{HR} > 10^6$ with nominal $P = 0$ and $\text{FDR} = 0$). Conversely, 3 features (`CENPVL3`, `LOC105372753`, `RP11-506K19.2`) exhibit saturated protective values ($\text{HR} = 1.929 \times 10^{-22}, P = 0, \text{FDR} = 0$).
* **Model Instability:** Such saturated effect sizes typically arise in Cox proportional hazards regression when a binary or low-expression feature experiences complete separation (e.g., zero events in one group or ultra-rare expression specifically in early-censored or early-event patients), unpenalized fitting on small subgroup samples, or unthresholded sparse non-coding transcripts.
* **Feature Composition:** A substantial fraction (>60%) of the list consists of pseudogenes (e.g., `S100A7P1`, `ALDH7A1P3`, `NF1P7`), small non-coding RNAs / spliceosomal snRNAs / snoRNAs (`RNU6-*`, `RNU4-*`, `RN7SKP*`, `RNA5SP*`, `Y_RNA`), lncRNAs (`LINC00454`, `LINC01672`, `LINC02787`), and unmapped Ensembl entries.
* **Interpretation Scope:** Direct statistical weights cannot be reliably compared quantitatively between features. Therefore, the subsequent multidimensional interpretation is treated strictly as an **exploratory biological prioritization** based on canonical gene annotations, functional ontology, and published disease literature. External statistical validation was not performed in an independent clinical cohort.

---

### 1. Overall Biological Interpretation

The feature profile associated with adverse overall survival in this hepatocellular carcinoma (HCC) dataset converges on four primary biological themes:

1. **Aberrant Developmental Transcription and Dedifferentiation:** Expression of non-hepatic transcription factors (`FOXR2`, `OTX2`, `FOXI1`) reflects high-grade cellular reprogramming, lineage plasticity, and loss of mature hepatocyte differentiation, which typically characterizes aggressive, stem-like HCC subtypes.
2. **Oncogenic Insulin/Growth Factor and Neuroendocrine Signaling:** Upregulation of `IRS4` (insulin receptor substrate 4) and neuroendocrine peptides (`CRH`, `CGB2`) indicates activation of downstream PI3K/AKT/MAPK signaling cascades and putative endocrine/autocrine growth stimulation within the tumor microenvironment.
3. **Ectopic GPCR Expression (Olfactory Receptor Repertoire):** Multiple olfactory receptors and pseudogenes (`OR2M7`, `OR5T2`, `OR5M10`, `OR5M6P`, `OR5M13P`, `OR11J6P`) are elevated, reflecting broad epigenetic derepression, chromatin remodeling, or ectopic G-protein-coupled receptor (GPCR) chemosensory signaling in malignant liver tissue.
4. **Non-Coding Transcriptome Dysregulation:** A marked accumulation of small non-coding RNAs (snRNAs, `Y_RNA`, `MIR182`) and intergenic non-coding transcripts suggests widespread RNA processing alterations, spliceosomal stress, and microRNA-mediated post-transcriptional silencing contributing to tumor aggressiveness.

---

### 2. Core Biological Programs

```
+----------------------------------------------------------------------------------------------------+
| CORE PROGRAM 1: Lineage Plasticity & Developmental Transcription (Risk-Associated)                 |
| Major Genes: FOXR2, OTX2, FOXI1                                                                    |
| Standard Pathway: GO:0006355 (Regulation of DNA-templated transcription); Reactome R-HSA-212436   |
| Biological Context: Ectopic activation of pioneer/lineage transcription factors indicates loss of   |
| mature hepatocyte identity and reactivation of embryonic programs driving poor OS.               |
| Evidence & Limitations: Direct input association + literature; lacks direct ChIP-seq validation.    |
+----------------------------------------------------------------------------------------------------+
| CORE PROGRAM 2: Insulin/IGF & Receptor Tyrosine Kinase Signaling (Risk-Associated)                 |
| Major Genes: IRS4, SLC1A6                                                                          |
| Standard Pathway: KEGG: hsa04910 (Insulin signaling pathway); Reactome R-HSA-74752                 |
| Biological Context: IRS4 acts as a constitutively active scaffold bypassing IRS1/2 feedback       |
| inhibition to hyperactivate PI3K/AKT/mTOR signaling in hepatocellular carcinoma.                   |
| Evidence & Limitations: Direct input association + String/Reactome mapping; unvalidated in vivo.   |
+----------------------------------------------------------------------------------------------------+
| CORE PROGRAM 3: Ectopic GPCR & Chemosensory Signaling (Risk-Associated)                            |
| Major Genes: OR2M7, OR5T2, OR5M10, OR5M6P, OR5M13P, OR11J6P                                        |
| Standard Pathway: KEGG: hsa04740 (Olfactory transduction); GO:0004930 (GPCR activity)              |
| Biological Context: Ectopic expression of olfactory GPCRs coupled to GNAL/GNB1/GNG13 heterotrimeric |
| G-proteins drives intracellular cAMP/Ca2+ flux and migration in solid tumors.                      |
| Evidence & Limitations: Direct input association + String interactome; potential epiphenomenon.   |
+----------------------------------------------------------------------------------------------------+
| CORE PROGRAM 4: Non-Coding RNA & Spliceosomal/RNP Assembly (Risk-Associated)                       |
| Major Genes: Y_RNA, MIR182, RNU6-1134P, RNU6-71P, RNU4-72P, RNU4-63P, RN7SKP270, RN7SKP289        |
| Standard Pathway: Reactome R-HSA-8953854 (Metabolism of RNA); GO:0030529 (Ribonucleoprotein comp.) |
| Biological Context: Elevated small non-coding RNAs and Y RNAs disrupt RNA surveillance, alternative|
| splicing, and promote chromosomal instability and microRNA-driven oncogenesis.                   |
| Evidence & Limitations: High representation in dataset; high risk of non-specific read mapping.    |
+----------------------------------------------------------------------------------------------------+
```

---

### 3. Key Genes and Interaction Modules

1. **`IRS4` (Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Central transducer in Insulin/RTK signaling. Unlike `IRS1`/`IRS2`, `IRS4` lacks canonical negative feedback phosphorylation sites and sustains downstream AKT phosphorylation, promoting tumor proliferation, resistance to apoptosis, and metabolic reprogramming.
   * *Relationship Type:* Pathway co-membership and regulatory interaction with PI3K/AKT signaling components.
2. **`FOXR2` (Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Forkhead box transcription factor involved in developmental lineage specification. Acts as an oncogene in multiple solid tumors by enhancing MYC transcriptional activity and promoting epithelial-to-mesenchymal transition (EMT).
   * *Relationship Type:* Protein interaction with chromatin modifier `KAT5` (evidenced in STRING network records) and putative regulatory transcriptional activator.
3. **`OTX2` (Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Homeobox transcription factor normally restricted to embryogenesis and neuroectodermal tissues. In HCC, ectopic expression indicates dedifferentiation and an aggressive stem-cell-like phenotype.
   * *Relationship Type:* Putative regulatory interaction; pathway co-membership in transcriptional regulation.
4. **`CRH` (Corticotropin Releasing Hormone; Hazard Ratio: $1.510 \times 10^6, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Neuroendocrine peptide signaling. Ectopic secretome components in HCC can alter local immunosuppression and vascular permeability via CRH receptor GPCR signaling.
   * *Relationship Type:* Regulatory ligand-receptor interaction; pathway co-membership.
5. **`MIR182` (Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* OncomiR in HCC. Post-transcriptionally suppresses negative regulators of cell cycle and metastasis (such as FOXO1, FOXO3, and MTSS1), thereby accelerating intrahepatic invasion and poor survival.
   * *Relationship Type:* Direct regulatory interaction (microRNA-target 3' UTR binding and mRNA degradation/repression).
6. **`SLC1A6` (EAAT4; Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* High-affinity sodium-dependent L-aspartate and L-glutamate transporter. Facilitates metabolic adaptation, amino acid influx, and antioxidant replenishment (glutathione synthesis pathway).
   * *Relationship Type:* Physical interaction with scaffold proteins `SPTBN2` and `KAT5` (STRING network); pathway co-membership in SLC-mediated amino acid transport.
7. **Olfactory GPCR Module (`OR2M7`, `OR5T2`, `OR5M10`; All HR: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Ectopically expressed GPCR cluster. In non-olfactory tissues, olfactory receptors activate non-canonical intracellular signaling (calcium influx, MAPK phosphorylation) upon binding endogenous metabolic ligands.
   * *Relationship Type:* Direct physical and functional interaction with downstream G-protein subunits (`GNAL`, `GNB1`, `GNG13`) and arrestins (`ARRB1`, `ARRB2`) based on STRING interactome records.
8. **`CGB2` (Chorionic Gonadotropin Subunit Beta 2; Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Ectopic beta-hCG expression is an established biomarker of embryonal differentiation, invasiveness, and chemoresistance in solid tumors.
   * *Relationship Type:* Extracellular ligand-receptor interaction with LH/CG receptors.
9. **`Y_RNA` (Hazard Ratio: $5.185 \times 10^{21}, P = 0, \text{FDR} = 0$)**
   * *Program & Role:* Small non-coding RNA involved in Ro60 ribonucleoprotein assembly, chromosomal DNA replication initiation, and cellular stress response.
   * *Relationship Type:* Direct physical interaction with Ro60 (TROVE2) and La (SSB) proteins.
10. **`CENPVL3` (Hazard Ratio: $1.929 \times 10^{-22}, P = 0, \text{FDR} = 0$)**
    * *Program & Role:* Centromere protein V-like pseudogene, one of the three protective-associated markers in the dataset.
    * *Relationship Type:* Putative indirect/regulatory non-coding transcript; biological role remains poorly characterized (insufficient evidence).

---

### 4. Validation Priorities

```
+----------------------------------------------------------------------------------------------------+
| 1. IRS4-Mediated PI3K/AKT Activation in HCC                                                        |
| Class: Mechanistic hypothesis / Therapeutic target                                                 |
| Current Evidence: High risk association (HR = 5.185e+21, P = 0) in uploaded dataset.               |
| External Context: IRS4 is well-documented to constitutively drive PI3K/AKT signaling.             |
| Next Step: Perform shRNA/CRISPR knockdown of IRS4 in HepG2/Huh7 cells, assaying p-AKT (Ser473).    |
| Adjudication Status: Supported hypothesis.                                                         |
+----------------------------------------------------------------------------------------------------+
| 2. Oncogenic Repression Profiling of MIR182 Targets                                                |
| Class: Biomarker / Mechanistic hypothesis                                                          |
| Current Evidence: High risk association (HR = 5.185e+21, P = 0) in uploaded dataset.               |
| External Context: Published literature confirms miR-182 promotes HCC invasion and poor prognosis.  |
| Next Step: Dual-luciferase reporter assays and qPCR validation of target suppression in liver tissue.|
| Adjudication Status: Supported hypothesis.                                                         |
+----------------------------------------------------------------------------------------------------+
| 3. Functional Impact of Ectopic Olfactory Receptor Activation (OR2M7 / OR5T2 / OR5M10)             |
| Class: Interaction / network hypothesis                                                            |
| Current Evidence: Consistent co-occurrence and identical saturated risk HRs across 6 OR genes.     |
| External Context: GPCR coupling to GNAL/GNB1 in solid tumors; literature in HCC is limited.        |
| Next Step: Calcium flux and cAMP reporter assays in HCC cell lines upon receptor overexpression.  |
| Adjudication Status: Exploratory hypothesis.                                                       |
+----------------------------------------------------------------------------------------------------+
| 4. Developmental TF Plasticity (FOXR2 / OTX2 / FOXI1) as Prognostic Signatures                     |
| Class: Biomarker                                                                                   |
| Current Evidence: Direct input risk association (HR = 5.185e+21, P = 0, FDR = 0).                 |
| External Context: Broad association of stemness and embryonal TFs with aggressive HCC recurrence.  |
| Next Step: Immunohistochemistry (IHC) on an independent HCC tissue microarray (TMA, n > 200).     |
| Adjudication Status: Exploratory hypothesis.                                                       |
+----------------------------------------------------------------------------------------------------+
| 5. Confounding and Read-Mapping Audit for Small Non-Coding & Pseudogene Transcripts                 |
| Class: Confounding or composition check                                                            |
| Current Evidence: >60% of input features are snRNAs, pseudogenes, and unmapped Ensembl IDs.        |
| External Context: Cross-hybridization and multi-mapping artifacts frequently inflate snRNA stats.  |
| Next Step: Re-alignment with strict unique-mapping criteria (STAR/Salmon) and penalization models. |
| Adjudication Status: Confounding check (High Priority).                                            |
+----------------------------------------------------------------------------------------------------+
```

---

### 5. Evidence Grounding & Adjudication

| Feature / Program | Direct Input Evidence | Pathway & Ontology Evidence | Network / Physical Interaction | Published Literature & Independent Status | Evidence Adjudication |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **`IRS4` / Insulin Signaling** | $\text{HR} = 5.185 \times 10^{21}$, $P=0$, $\text{FDR}=0$ | KEGG: Type II diabetes, Insulin signaling | STRING: Interactome with PI3K complex | Documented oncogene in cancer; external validation in this dataset: *not performed* | **Supported hypothesis** |
| **`MIR182`** | $\text{HR} = 5.185 \times 10^{21}$, $P=0$, $\text{FDR}=0$ | GO: Post-transcriptional gene silencing | TargetScan/miRBase: 3' UTR repression | Validated prognostic microRNA across multiple independent HCC cohorts in literature | **Supported hypothesis** |
| **`FOXR2` / `OTX2` TFs** | $\text{HR} = 5.185 \times 10^{21}$, $P=0$, $\text{FDR}=0$ | Reactome: Generic gene transcription | STRING: FOXR2-KAT5 chromatin interaction | Known driver of MYC/EMT in neural/solid tumors; direct HCC evidence is exploratory | **Exploratory hypothesis** |
| **Olfactory Receptors (`OR2M7`, `OR5T2`, `OR5M10`)** | $\text{HR} = 5.185 \times 10^{21}$, $P=0$, $\text{FDR}=0$ | GO: Olfactory transduction, GPCR signaling | STRING: Direct coupling to GNAL, GNB1, ARRB1 | Ectopic GPCR expression in cancers reported; no causal mechanistic proof in liver | **Exploratory hypothesis** |
| **Small RNAs / Pseudogenes (`RNU*`, `RNA5S*`, `LOC*`)** | Extreme HRs ($>10^6$ to $10^{21}$ / $<10^{-21}$) | Reactome: Metabolism of RNA | High stringency PPI: *None* | High risk of alignment artifacts and low-expression zero-inflation | **Insufficient evidence** |

---

### 6. Limitations and Alternative Explanations

1. **Statistical Artifacts and Unregularized Separation:** The presence of identical hazard ratios ($\text{HR} = 5.185 \times 10^{21}$) across dozens of distinct transcripts indicates numerical instability (quasi-complete separation in the Cox model). This occurs when transcripts with very low read counts happen to be non-zero exclusively in patients with early events. Firth’s penalized Cox regression or regularized Elastic Net Cox models should be applied to recalculate unbiased effect sizes.
2. **Sequencing Multi-Mapping and Alignment Ambiguity:** Features such as `RNU6-*`, `RNU4-*`, `RN7SKP*`, and unmapped Ensembl entries share high sequence homology across repetitive genomic loci. Short-read RNA-seq alignment tools can misassign multi-mapping reads, artificially creating pseudo-biomarkers.
3. **Tumor Purity and Microenvironment Deconvolution:** Solid liver tumor biopsies contain varying proportions of hepatocytes, tumor-infiltrating lymphocytes, hepatic stellate cells, and endothelial cells. Elevated neuroendocrine and metabolic signals (`CRH`, `SLC1A6`) could reflect infiltrating immune or stromal subsets rather than tumor-intrinsic transcription. Single-cell RNA-seq or digital spatial profiling is required to resolve cellular provenance.
4. **Epigenetic Derepression vs. Functional Driver Status:** High-grade HCC is characterized by global DNA hypomethylation and loss of heterochromatin organization, leading to broad, non-functional transcriptional leakage of lineage-forbidden genes (such as olfactory receptors and pseudogenes). These signals may represent passive epiphenomena of genomic decay rather than functional drivers of tumor progression.
5. **Absence of Independent Cohort Validation:** External statistical validation was not performed in an independent clinical cohort for this specific ledger; therefore, prognostic associations remain preliminary candidate signatures until confirmed on independent, clinical-grade survival datasets (such as TCGA-LIHC or ICGC LIRI-JP).

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=15, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
